Your browser doesn't support javascript.
loading
Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization.
Yang, Jing; Lin, Sheng; Chen, Zimin; Yang, Fanli; Guo, Liyan; Wang, Lingling; Duan, Yanping; Zhang, Xindan; Dai, Yushan; Yin, Keqing; Yu, Chongzhang; Yuan, Xin; Sun, Honglu; He, Bin; Cao, Yu; Ye, Haoyu; Dong, Haohao; Liu, Xianbo; Chen, Bo; Li, Jian; Zhao, Qi; Lu, Guangwen.
Afiliação
  • Yang J; Department of Emergency Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Lin S; Department of Emergency Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Chen Z; Department of Emergency Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Yang F; Department of Emergency Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Guo L; Department of Emergency Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Wang L; Department of Emergency Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Duan Y; Department of Emergency Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Zhang X; Department of Emergency Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Dai Y; Department of Emergency Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Yin K; Department of Emergency Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Yu C; Department of Emergency Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Yuan X; Department of Emergency Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Sun H; Department of Emergency Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • He B; Department of Emergency Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Cao Y; Department of Emergency Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Ye H; Disaster Medicine Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Dong H; Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Liu X; State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Chen B; CHENGDU NB BIOLAB CO., LTD, Chengdu, Sichuan, China.
  • Li J; CHENGDU NB BIOLAB CO., LTD, Chengdu, Sichuan, China.
  • Zhao Q; School of Basic Medical Sciences, Chengdu University, Chengdu, Sichuan, China.
  • Lu G; College of Food and Biological Engineering, Chengdu University, Chengdu, Sichuan, China.
PLoS Pathog ; 19(11): e1011804, 2023 Nov.
Article em En | MEDLINE | ID: mdl-38033141
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos de Domínio Único / COVID-19 Limite: Humans Idioma: En Revista: PLoS Pathog Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos de Domínio Único / COVID-19 Limite: Humans Idioma: En Revista: PLoS Pathog Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China